An international team of researchers said a clinical study shows a three-in-one Indian pill, Cipla's Triomune, did as well as the more expensive branded drugs, leading them to advocate its use in developing countries. The study, conducted in Cameroon, may help answer concerns about the effectiveness of generic fixed-dose combinations. Those concerns have led some international AIDS donors to reject funding for the generic pills.

Related Summaries